• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

Introduction to N1, N12-Diethylsperminemiddle dot 4HCl (CAS No. 113812-15-0)

N1, N12-Diethylsperminemiddle dot 4HCl (CAS No. 113812-15-0) is a compound of significant interest in the field of pharmaceutical chemistry and biochemistry. This compound, characterized by its unique structural and chemical properties, has garnered attention for its potential applications in various biological and medical research areas. The diethyl derivative of spermine, combined with the presence of a hydrochloride salt form, imparts distinct pharmacological characteristics that make it a valuable candidate for further investigation.

The molecular structure of N1, N12-Diethylsperminemiddle dot 4HCl consists of a spermine backbone with two ethyl groups attached at the N1 and N12 positions. This modification enhances the solubility and stability of the compound, making it more suitable for formulation in pharmaceutical applications. The hydrochloride salt form further improves its solubility in aqueous solutions, facilitating its use in drug delivery systems and biochemical assays.

In recent years, there has been growing interest in the role of polyamine derivatives in modulating cellular processes and treating various diseases. Polyamines, such as spermine and its derivatives, are naturally occurring organic cations that play crucial roles in cell growth, differentiation, and apoptosis. Among these, spermine derivatives have shown promise in inhibiting the activity of certain enzymes and pathways involved in cancer progression and inflammation.

N1, N12-Diethylsperminemiddle dot 4HCl has been studied for its potential anti-inflammatory and anticancer properties. Preclinical studies have demonstrated that this compound can inhibit the activity of matrix metalloproteinases (MMPs), which are enzymes involved in tissue degradation and inflammation. By targeting MMPs, this compound may help reduce inflammation and prevent the progression of certain chronic diseases.

Additionally, the compound has shown potential in inhibiting the growth of various cancer cell lines. Research indicates that N1, N12-Diethylsperminemiddle dot 4HCl can disrupt cancer cell proliferation by interfering with key signaling pathways involved in cell cycle regulation. This makes it a promising candidate for further development as an anticancer agent.

The synthesis of N1, N12-Diethylsperminemiddle dot 4HCl involves a multi-step process that requires precise control over reaction conditions to ensure high yield and purity. The synthesis typically begins with the condensation of diamines followed by alkylation to introduce the ethyl groups at the specified positions. The final step involves converting the free base into its hydrochloride salt to enhance stability and solubility.

In terms of pharmacokinetics, N1, N12-Diethylsperminemiddle dot 4HCl exhibits moderate bioavailability when administered orally or intravenously. Studies have shown that the compound is rapidly absorbed into the bloodstream and distributed throughout various tissues. However, its half-life is relatively short, necessitating repeated dosing for sustained therapeutic effects.

The safety profile of N1, N12-Diethylsperminemiddle dot 4HCl has been evaluated through preclinical toxicity studies. These studies have revealed that the compound is generally well-tolerated at therapeutic doses but may cause some side effects at higher concentrations. Common side effects include nausea, vomiting, and gastrointestinal discomfort. Further clinical trials are needed to fully assess its safety and efficacy in human populations.

Recent advancements in drug delivery systems have opened new possibilities for enhancing the therapeutic potential of N1, N12-Diethylsperminemiddle dot 4HCl. Nanoparticle-based formulations have shown promise in improving drug solubility and targeting specific cells or tissues. Additionally, prodrug strategies have been explored to enhance bioavailability and reduce side effects.

The future directions for research on N1, N12-Diethylsperminemiddle dot 4HCl include exploring its mechanisms of action in greater detail. Understanding how this compound interacts with cellular targets will provide insights into its therapeutic potential and help identify new applications. Furthermore, combination therapies involving N1, N12-Diethylsperminemiddle dot 4HCl with other drugs may offer synergistic effects that could improve treatment outcomes for various diseases.

In conclusion, N1, N12-Diethylsperminemiddle dot 4HCl (CAS No. 113812-15-0) is a promising compound with significant potential in pharmaceutical applications. Its unique structure and chemical properties make it a valuable tool for research in anti-inflammatory and anticancer therapies. As further studies continue to uncover its therapeutic benefits and optimize its delivery systems, this compound is poised to play a crucial role in future medical treatments.

• 70862-11-2(1,4-Butanediamine,N1-[3-[(3-aminopropyl)amino]propyl]-)
• 71-44-3(Spermine)
• 68956-56-9(dipentene fluka spec. purified fraction of terpene hydrocarb)
• 124-20-9(Spermidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)